Suscribirse

The IRAD Classification System for Characterizing Survival after Aortic Dissection - 23/07/13

Doi : 10.1016/j.amjmed.2013.01.020 
Anna M. Booher, MD a, , Eric M. Isselbacher, MD b, Christoph A. Nienaber, MD c, Santi Trimarchi, MD d, Arturo Evangelista, MD e, Daniel G. Montgomery, BS a, James B. Froehlich, MD, MPH a, Marek P. Ehrlich, MD f, Jae K. Oh, MD g, James L. Januzzi, MD b, Patrick O'Gara, MD h, Thoralf M. Sundt, MD b, Kevin M. Harris, MD i, Eduardo Bossone, MD, PhD j, Reed E. Pyeritz, MD, PhD k, Kim A. Eagle, MD a

IRAD Investigators

a Department of Internal Medicine, University of Michigan, Ann Arbor 
b Thoracic Aortic Center, Massachusetts General Hospital, Boston 
c Department of Internal Medicine, University Hospital Eppendorf-Rostock, Germany 
d Thoracic Aortic Research Center, IRCCS Policlinico San Donato, San Donato, Italy 
e Department of Cardiology, Hospital General Universitari Vall D'Hebron, Barcelona, Spain 
f Department of Cardiothoracic Surgery, University of Vienna, Austria 
g Department of Internal Medicine, Mayo Clinic, Rochester, Minn 
h Department of Cardiology, Brigham & Women's Hospital, Boston, Mass 
i Department of Cardiology, Minneapolis Heart Institute, Minneapolis, Minn 
j Department of Cardiology, San Giovanni e Ruggi, Salerno, Italy 
k Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 

Requests for reprints should be addressed to Anna M. Booher, MD, University of Michigan Cardiovascular Center, 2344 Cardiovascular Center, SPC 5853, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-5853.

Abstract

Background

The classification of aortic dissection into acute (<14 days from symptom onset) versus chronic (≥14 days) is based on survival estimates of patients treated decades before modern diagnostic and treatment modalities were available. A new classification of aortic dissection in the current era may provide clinicians with a more precise method of characterizing the interaction of time, dissection location, and treatment type with survival.

Methods

We developed separate Kaplan-Meier survival curves for Type A and Type B aortic dissection using data from the International Registry of Aortic Dissection (IRAD). Daily survival was stratified based on type of therapy provided: medical therapy alone (medical), nonsurgical intervention plus medical therapy (endovascular), and open surgery plus medical therapy (surgical). The log-rank statistic was used to compare the survival curves of each management type within Type A and Type B aortic dissection.

Results

There were 1815 patients included, 67.3% male with mean age 62.0 ± 14.2 years. When survival curves were constructed, 4 distinct time periods were noted: hyperacute (symptom onset to 24 hours), acute (2-7 days), subacute (8-30 days), and chronic (>30 days). Overall survival was progressively lower through the 4 time periods.

Conclusions

This IRAD classification system can provide clinicians with a more robust method of characterizing survival after aortic dissection over time than previous methods. This system will be useful for treating patients, counseling patients and families, and studying new diagnostic and treatment methods.

El texto completo de este artículo está disponible en PDF.

Keywords : Aorta, Dissecting aneurysm, Survival analyses, Thoracic surgery


Esquema


 Funding: IRAD is supported by grants from the University of Michigan Health System, the Varbedian Fund for Aortic Research, the Hewlett Foundation, the Mardigian Foundation, and Gore Inc.
 Conflict of Interest: AMB, EMI, CAN, ST, AE, DGM, MPE, JKO, PG, TMS, KMH, EB, and REP have no conflicts of interest to report. JBF: Research Grants—SanofiAventis, Blue Cross/Blue Shield of Michigan, Mardigian Foundation, Fibromuscular Disease Society of America; Consulting—SanofiAventis, Ortho-McNeil, and Merck. JLJ: Grants—Roche, Siemens, Critical Diagnostics; Consulting—Roche and Critical Diagnostics; Speaking—Roche (all significant). KAE: Grant/Research Support—Bristol Myers Squibb, Blue Cross Blue Shield of Michigan, GORE (significant), Hewlett Foundation, Mardigian Fund, SanofiAventis, Varbedian Fund; Consultant—NIH NHLBI, SanofiAventis.
 Authorship: All authors had access to the data and a role in writing the manuscript.


© 2013  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 126 - N° 8

P. 730.e19-730.e24 - août 2013 Regresar al número
Artículo precedente Artículo precedente
  • Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-? Blockade with Nonbiologic DMARDs
  • Daniel H. Solomon, Jeffrey R. Curtis, Kenneth G. Saag, Joyce Lii, Lang Chen, Leslie R. Harrold, Lisa J. Herrinton, David J. Graham, Mary K. Kowal, Bindee Kuriya, Liyan Liu, Marie R. Griffin, James D. Lewis, Jeremy A. Rassen
| Artículo siguiente Artículo siguiente
  • Unexplained Hypoxia in a Woman Presenting with Acute on Chronic Abdominal Pain
  • Wassim Shatila, Alicia Clark

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.